Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Irbesartan (Primary)
- Indications Atrial fibrillation
- Focus Pharmacodynamics
- Acronyms CREATIVE-AF
- 07 Jun 2017 Biomarkers information updated
- 23 Jun 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-003262-17).